The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 14, 2006
Filed:
Nov. 03, 1997
Craig J. Gerard, Dover, MA (US);
Norma P. Gerard, Dover, MA (US);
Charles R. Mackay, Watertown, MA (US);
Paul D. Ponath, Boston, MA (US);
Theodore W. Post, Newton, MA (US);
Shixin Qin, Lexington, MA (US);
Craig J. Gerard, Dover, MA (US);
Norma P. Gerard, Dover, MA (US);
Charles R. Mackay, Watertown, MA (US);
Paul D. Ponath, Boston, MA (US);
Theodore W. Post, Newton, MA (US);
Shixin Qin, Lexington, MA (US);
Children's Medical Center Corp., Boston, MA (US);
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Brigham & Women's Hospital, Boston, MA (US);
Abstract
The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.